Dermata Therapeutics, Inc. (DRMA): Price and Financial Metrics
GET POWR RATINGS... FREE!
DRMA Stock Price Chart Interactive Chart >
DRMA Price/Volume Stats
| Current price | $0.70 | 52-week high | $6.95 |
| Prev. close | $0.69 | 52-week low | $0.62 |
| Day low | $0.65 | Volume | 21,900 |
| Day high | $0.73 | Avg. volume | 412,280 |
| 50-day MA | $1.07 | Dividend yield | N/A |
| 200-day MA | $0.00 | Market Cap | 6.46M |
Dermata Therapeutics, Inc. (DRMA) Company Bio
Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the treatment of medical and aesthetic skin conditions. Its lead product candidate is DMT310, a once-weekly topical product that is under clinical development for the treatment of acne vulgaris, psoriasis vulgaris, and papulopustular rosacea. The company was founded in 2014 and is headquartered in San Diego, California.
Latest DRMA News From Around the Web
Below are the latest news stories about Dermata Therapeutics Inc that investors may wish to consider to help them evaluate DRMA as an investment opportunity.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on ThursdayGood morning, trader! |
Dermata, Innoviva top healthcare gainers; while InfuSystem, Seagen lead losers packGainers: Dermata Therapeutics DRMA +35%. Innoviva (INVA) +11%. Mainz Biomed (MYNZ) +9%. Regional Health Properties RHE +9%. Envista Holdings (NVST) +8%.Losers: InfuSystem |
Thinking about buying stock in Dermata Therapeutics, Ironnet, Preferred Apartment Communities, Mattel, or Viking Therapeutics?NEW YORK , Feb. 10, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for DRMA, IRNT, APTS, MAT, and VKTX. Full story available on Benzinga.com |
IceCure Medical, Atossa top healthcare gainers; Dermata, Statera among losersIceCure Medical ICCM +16%. Atossa Therapeutics (ATOS) +15%. Dermata Therapeutics (DRMA) -31%. Statera Biopharma STAB -26%. |
Dermata Therapeutics Shares Plunge 20% Premarket: What Investors Need To KnowDermata Therapeutics Inc (NASDAQ: DRMA ) has requested the FDA to waive the requirements to complete a 90-day dermal minipig study and a standard dermal pharmacokinetics study before the End of Phase 2 meeting for its DMT310 acne program. The Company said it has already planned and budgeted to conduct both studies. The requests come as DMT310 has been used in clinical trials by over 170 patients exhibiting an acceptable safety and tolerability profile. Further, the FDA approved the Company … Full story available on Benzinga.com |
DRMA Price Returns
| 1-mo | -44.88% |
| 3-mo | N/A |
| 6-mo | -69.96% |
| 1-year | N/A |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -59.77% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...